Ultragenyx Pharmaceu (RARE) 52.13 $RARE
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 230.31 (+1.76), RARE: 52.13 (-0.27)
Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Ultragenyx to license and develop one or more product candidates from Takeda
RARE: 52.13 (-0.27)
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 52.13 (-0.27), ANIP: 56.06 (+3.27)
Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
RARE: 52.13 (-0.27)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.37 (-0.03), RARE: 52.13 (-0.27), ICPT: 151.88 (+3.78), JUNO: 42.95 (+0.33)
Ultragenyx reports 1Q loss
Automated Insights - Mon May 09, 3:25PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $52.8 million in its first quarter.
RARE: 52.13 (-0.27)
Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon May 09, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
RARE: 52.13 (-0.27)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Fri May 06, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 11, 2016 at 1:00pm PT in Las Vegas, NV.
RARE: 52.13 (-0.27)
Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and provide a corporate update.
RARE: 52.13 (-0.27)
Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Initial data from the first eight patients in the study, including one patient with epidermal nevus syndrome (ENS), demonstrated that KRN23 improved serum phosphorus levels and other bone metabolism measures. The study has been expanded to enroll approximately 15 patients, and enrollment is ongoing.
RARE: 52.13 (-0.27)
Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment
GlobeNewswire - Wed Mar 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University's (SLU) Center for World Health and Medicine, today announced that they have entered into three-year sponsored research and option agreements to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
RARE: 52.13 (-0.27)
Ultragenyx Appoints Lars Ekman, M.D., Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 21, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Lars Ekman, M.D., Ph.D., to the company's Board of Directors effective March 17, 2016. Dr. Ekman, Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx.
RARE: 52.13 (-0.27)
Ultragenyx to Present at the Cowen and Company 36th Annual Health Care Conference
GlobeNewswire - Wed Mar 02, 3:05PM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 36 Annual Health Care Conference on Monday, March 7, 2016 at 4:00pm ET at the Boston Marriott Copley Place in Boston, MA.
RARE: 52.13 (-0.27)
Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
GlobeNewswire - Tue Feb 09, 7:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the LEERINK Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
RARE: 52.13 (-0.27)
Why Ultragenyx Pharmaceuticals Skyrocketed in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Fri Jan 15, 1:03PM CST
What: 2015 was a great year to be a shareholder of Ultragenyx Pharmaceutical , a clinical-stage biopharmaceutical company focused on developing therapies to treat rare diseases. Investors enjoyed a 141% return during the year, according to data...
RARE: 52.13 (-0.27), ALXN: 122.43 (+1.02)
Ultragenyx Pharmaceutical (RARE) in Focus: Stock Tumbles 11.2%
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 7:51AM CST
Ultragenyx Pharmaceutical's shares fell by over 11% in the last session, and the stock is now down almost 25% in the past one-month time frame
RARE: 52.13 (-0.27), ANIK: 50.94 (+0.67)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 230.31 (+1.76), RARE: 52.13 (-0.27)
Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Ultragenyx to license and develop one or more product candidates from Takeda
RARE: 52.13 (-0.27)
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 52.13 (-0.27), ANIP: 56.06 (+3.27)
Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
RARE: 52.13 (-0.27)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.37 (-0.03), RARE: 52.13 (-0.27), ICPT: 151.88 (+3.78), JUNO: 42.95 (+0.33)
Ultragenyx reports 1Q loss
Automated Insights - Mon May 09, 3:25PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $52.8 million in its first quarter.
RARE: 52.13 (-0.27)
Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon May 09, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
RARE: 52.13 (-0.27)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Fri May 06, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 11, 2016 at 1:00pm PT in Las Vegas, NV.
RARE: 52.13 (-0.27)
Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and provide a corporate update.
RARE: 52.13 (-0.27)
Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Initial data from the first eight patients in the study, including one patient with epidermal nevus syndrome (ENS), demonstrated that KRN23 improved serum phosphorus levels and other bone metabolism measures. The study has been expanded to enroll approximately 15 patients, and enrollment is ongoing.
RARE: 52.13 (-0.27)
Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment
GlobeNewswire - Wed Mar 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University's (SLU) Center for World Health and Medicine, today announced that they have entered into three-year sponsored research and option agreements to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
RARE: 52.13 (-0.27)
Ultragenyx Appoints Lars Ekman, M.D., Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 21, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Lars Ekman, M.D., Ph.D., to the company's Board of Directors effective March 17, 2016. Dr. Ekman, Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx.
RARE: 52.13 (-0.27)
Ultragenyx to Present at the Cowen and Company 36th Annual Health Care Conference
GlobeNewswire - Wed Mar 02, 3:05PM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 36 Annual Health Care Conference on Monday, March 7, 2016 at 4:00pm ET at the Boston Marriott Copley Place in Boston, MA.
RARE: 52.13 (-0.27)
Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
GlobeNewswire - Tue Feb 09, 7:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the LEERINK Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
RARE: 52.13 (-0.27)
Why Ultragenyx Pharmaceuticals Skyrocketed in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Fri Jan 15, 1:03PM CST
What: 2015 was a great year to be a shareholder of Ultragenyx Pharmaceutical , a clinical-stage biopharmaceutical company focused on developing therapies to treat rare diseases. Investors enjoyed a 141% return during the year, according to data...
RARE: 52.13 (-0.27), ALXN: 122.43 (+1.02)
Ultragenyx Pharmaceutical (RARE) in Focus: Stock Tumbles 11.2%
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 7:51AM CST
Ultragenyx Pharmaceutical's shares fell by over 11% in the last session, and the stock is now down almost 25% in the past one-month time frame
RARE: 52.13 (-0.27), ANIK: 50.94 (+0.67)
